RAPT Therapeutics Inc

+0.67 (+2.07%)
Products, Earnings Announcements

RAPT Therapeutics Announces Late-Breaking Oral Presentation Of Positive Results From Phase 1B Trial Of RPT193

Published: 09/30/2021 13:32 GMT
RAPT Therapeutics Inc (RAPT) - Rapt Therapeutics Announces Late-breaking Oral Presentation of Positive Results From Phase 1b Trial of Rpt193 at 30th European Academy of Dermatology and Venereology Congress.
Rapt Therapeutics Inc - Rpt193 Was Well Tolerated in Phase 1b Study.
Rapt Therapeutics Inc - No Serious Adverse Events Were Reported, and All Adverse Events Reported Were Mild Or Moderate in Intensity.
Revenue is expected to be $0.78 Million
Adjusted EPS is expected to be -$0.62

Next Quarter Revenue Guidance is expected to be $0.54 Million
Next Quarter EPS Guidance is expected to be -$0.69

More details on our Analysts Page.